{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:05:32Z","timestamp":1793106332111,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,5,30]],"date-time":"2014-05-30T00:00:00Z","timestamp":1401408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"},{"start":{"date-parts":[[2014,5,30]],"date-time":"2014-05-30T00:00:00Z","timestamp":1401408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2014.34","type":"journal-article","created":{"date-parts":[[2014,5,30]],"date-time":"2014-05-30T13:19:17Z","timestamp":1401455957000},"page":"e214-e214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas"],"prefix":"10.1038","volume":"4","author":[{"given":"R","family":"Briski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A L","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N G","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Ristow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T M","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W R","family":"Macon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D J","family":"Inwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J P","family":"Colgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G S","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T E","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S M","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,30]]},"reference":[{"key":"BFbcj201434_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D . International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124\u20134130.","journal-title":"J Clin Oncol"},{"key":"BFbcj201434_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFbcj201434_CR3","doi-asserted-by":"crossref","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"BFbcj201434_CR4","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM . Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15: 1467\u20131475.","journal-title":"Ann Oncol"},{"key":"BFbcj201434_CR5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/10428190290016926","volume":"43","author":"M Reiser","year":"2002","unstructured":"Reiser M, Josting A, Soltani M, Staib P, Salzberger B, Diehl V et al. T-cell non-Hodgkin\u2019s lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma 2002; 43: 805\u2013811.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201434_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12185-013-1383-z","volume":"98","author":"Y Torimoto","year":"2013","unstructured":"Torimoto Y, Sato K, Ikuta K, Hayashi T, Hirayama Y, Inamura J et al. A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group. Int J Hematol 2013; 98: 171\u2013178.","journal-title":"Int J Hematol"},{"key":"BFbcj201434_CR7","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"MP Escalon","year":"2005","unstructured":"Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005; 103: 2091\u20132098.","journal-title":"Cancer"},{"key":"BFbcj201434_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdq359","volume":"22","author":"G Gutierrez-Garcia","year":"2011","unstructured":"Gutierrez-Garcia G, Garcia-Herrera A, Cardesa T, Martinez A, Villamor N, Ghita G et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol 2011; 22: 397\u2013404.","journal-title":"Ann Oncol"},{"key":"BFbcj201434_CR9","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.3109\/10428190903318311","volume":"50","author":"D Chihara","year":"2009","unstructured":"Chihara D, Oki Y, Ine S, Yamamoto K, Kato H, Taji H et al. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma 2009; 50: 1999\u20132004.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201434_CR10","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011; 117: 3402\u20133408.","journal-title":"Blood"},{"key":"BFbcj201434_CR11","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474\u20132479.","journal-title":"Blood"},{"key":"BFbcj201434_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00277-008-0544-2","volume":"88","author":"Y Lee","year":"2009","unstructured":"Lee Y, Uhm JE, Lee HY, Park MJ, Kim H, Oh SJ et al. Clinical features and prognostic factors of patients with \u201cperipheral T cell lymphoma, unspecified\u201d. Ann Hematol 2009; 88: 111\u2013119.","journal-title":"Ann Hematol"},{"key":"BFbcj201434_CR13","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1097\/01.pas.0000173238.17331.6b","volume":"29","author":"N Asano","year":"2005","unstructured":"Asano N, Suzuki R, Kagami Y, Ishida F, Kitamura K, Fukutani H et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 2005; 29: 1284\u20131293.","journal-title":"Am J Surg Pathol"},{"key":"BFbcj201434_CR14","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1023\/A:1008418727472","volume":"9","author":"A Lopez-Guillermo","year":"1998","unstructured":"Lopez-Guillermo A, Cid J, Salar A, Lopez A, Montalban C, Castrillo JM et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 1998; 9: 849\u2013855.","journal-title":"Ann Oncol"},{"key":"BFbcj201434_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/annonc\/mdf033","volume":"13","author":"T Rudiger","year":"2002","unstructured":"Rudiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin\u2019s Lymphoma Classification Project. Ann Oncol 2002; 13: 140\u2013149.","journal-title":"Ann Oncol"},{"key":"BFbcj201434_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/hon.853","volume":"26","author":"N Niitsu","year":"2008","unstructured":"Niitsu N, Okamoto M, Nakamine H, Aoki S, Motomura S, Hirano M . Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematol Oncol 2008; 26: 152\u2013158.","journal-title":"Hematol Oncol"},{"key":"BFbcj201434_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1023\/A:1008200307625","volume":"8","author":"S Ascani","year":"1997","unstructured":"Ascani S, Zinzani PL, Gherlinzoni F, Sabattini E, Briskomatis A, de Vivo A et al. Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann Oncol 1997; 8: 583\u2013592.","journal-title":"Ann Oncol"},{"key":"BFbcj201434_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00277-002-0450-y","volume":"81","author":"J Pellatt","year":"2002","unstructured":"Pellatt J, Sweetenham J, Pickering RM, Brown L, Wilkins B . A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin\u2019s lymphoma. Ann Hematol 2002; 81: 267\u2013272.","journal-title":"Ann Hematol"},{"key":"BFbcj201434_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0959-8049(01)00344-6","volume":"38","author":"K Kim","year":"2002","unstructured":"Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer 2002; 38: 75\u201381.","journal-title":"Eur J Cancer"},{"key":"BFbcj201434_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/annonc\/mdi037","volume":"16","author":"WY Au","year":"2005","unstructured":"Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 2005; 16: 206\u2013214.","journal-title":"Ann Oncol"},{"key":"BFbcj201434_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/1042819021000030054","volume":"44","author":"ER Arrowsmith","year":"2003","unstructured":"Arrowsmith ER, Macon WR, Kinney MC, Stein RS, Goodman SA, Morgan DS et al. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. Leuk Lymphoma 2003; 44: 241\u2013249.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201434_CR22","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116: 3418\u20133425.","journal-title":"Blood"},{"key":"BFbcj201434_CR23","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3109\/10428194.2012.742521","volume":"54","author":"FM Foss","year":"2013","unstructured":"Foss FM, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith MR et al. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk Lymphoma 2013; 54: 1373\u20131379.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201434_CR24","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3109\/10428194.2013.816700","volume":"55","author":"K Ganjoo","year":"2013","unstructured":"Ganjoo K, Hong F, Horning SJ, Gascoyne RD, Natkunam Y, Swinnen LJ et al. Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma 2013; 55: 768\u2013772.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201434_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/cncr.27733","volume":"119","author":"D Mahadevan","year":"2013","unstructured":"Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, LeBlanc M et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 2013; 119: 371\u2013379.","journal-title":"Cancer"},{"key":"BFbcj201434_CR26","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","volume":"120","author":"YL Kwong","year":"2012","unstructured":"Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E et al. SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012; 120: 2973\u20132980.","journal-title":"Blood"},{"key":"BFbcj201434_CR27","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d'Amore","year":"2012","unstructured":"d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012; 30: 3093\u20133099.","journal-title":"J Clin Oncol"},{"key":"BFbcj201434_CR28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012; 30: 631\u2013636.","journal-title":"J Clin Oncol"},{"key":"BFbcj201434_CR29","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O'Connor","year":"2011","unstructured":"O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011; 29: 1182\u20131189.","journal-title":"J Clin Oncol"},{"key":"BFbcj201434_CR30","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30: 2190\u20132196.","journal-title":"J Clin Oncol"},{"key":"BFbcj201434_CR31","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3109\/10428194.2011.573031","volume":"52","author":"PL Zinzani","year":"2011","unstructured":"Zinzani PL, Pellegrini C, Broccoli A, Stefoni V, Gandolfi L, Quirini F et al. Lenalidomide monotherapy for relapsed\/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma 2011; 52: 1585\u20131588.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201434_CR32","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1023\/A:1008409601731","volume":"9","author":"PL Zinzani","year":"1998","unstructured":"Zinzani PL, Magagnoli M, Bendandi M, Orcioni GF, Gherlinzoni F, Albertini P et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.[see comment]. Ann Oncol 1998; 9: 1351\u20131353.","journal-title":"Ann Oncol"},{"key":"BFbcj201434_CR33","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30: 837\u2013842.","journal-title":"J Clin Oncol"},{"key":"BFbcj201434_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11899-012-0124-3","volume":"7","author":"K Tobinai","year":"2012","unstructured":"Tobinai K, Takahashi T, Akinaga S . Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. Curr Hematol Malig Rep 2012; 7: 235\u2013240.","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201434.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201434","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201434.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:54:39Z","timestamp":1672959279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,30]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5]]}},"alternative-id":["BFbcj201434"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2014.34","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,30]]},"assertion":[{"value":"10 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}